Phase I/Ib trial of durvalumab (MEDI4736), tremelimumab + cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (OBERON)
Phase of Trial: Phase I
Latest Information Update: 28 Mar 2019
Price : $35 *
At a glance
- Drugs Cetuximab (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Head and neck cancer; Squamous cell cancer
- Focus Adverse reactions
- Acronyms OBERON
- 15 Jan 2019 Recruitment completion is expected on 14 Jan 2021 according to ISRCTN: Current Controlled Trials.
- 15 Jan 2019 Status changed from not yet recruiting to recruiting.
- 17 Nov 2018 New trial record